ÂÜÀòÂÒÂ×

Thomas W. Chalberg, PhD has an extensive work experience in the biotechnology and medical industry. Thomas W. is currently a Partner at Polymerase Capital and the Founder/CEO of Genascence Corporation. Prior to these roles, they served as the Executive Chairman of iRenix Medical, Inc. and as a Director at Chameleon Biosciences, Inc. and ethris GmbH.

Thomas also founded SightGlass Vision, Inc., where they served as Founder, CEO, and Chief Scientific Officer. Under their leadership, the company developed innovative treatments for myopia in children and was eventually acquired in 2021. Before founding SightGlass Vision, they were the Chief Operating Officer (Interim) at Oncorus, Inc.

Thomas has a strong background in gene therapy for eye diseases, having founded Avalanche Biotechnologies, Inc. (now Adverum) and serving as its CEO. During their tenure, they built a platform for the discovery, development, and manufacturing of adeno-associated vectors (AAV) for retinal disease.

Early in their career, Thomas gained experience in marketing and commercial operations at Genentech, specifically in the ophthalmology and oncology divisions. Thomas W. also worked as a Biotechnology Consultant at ZS Associates.

Overall, Thomas W. Chalberg, PhD has played key leadership roles in various companies within the biotechnology and medical sectors, demonstrating their expertise in developing innovative treatments and driving business growth.

Thomas W. Chalberg, PhD, completed their Bachelor of Arts degree in Biochemical Sciences at Harvard University from 1995 to 1999. Thomas W. then attended Campolindo High School from 1991 to 1995 for their secondary education. Later, they pursued their PhD in Cancer Biology, Genetics, and Ophthalmology at Stanford University School of Medicine from 2001 to 2005. Finally, they obtained their Master of Business Administration (MBA) with a focus on Entrepreneurship and Biotechnology from the University of California, Berkeley, Haas School of Business, between 2008 and 2011.